目的 對(duì)多格列艾汀、二甲雙胍和利格列汀進(jìn)行臨床綜合評(píng)價(jià),為醫(yī)療機(jī)構(gòu)遴選藥品提供依據(jù)。方法 依據(jù)《中國(guó)醫(yī)療機(jī)構(gòu)藥品評(píng)價(jià)與遴選快速指南(第二版)》,從藥學(xué)特性、有效性、安全性、經(jīng)濟(jì)性和其他屬性方面進(jìn)行評(píng)分,根據(jù)評(píng)分結(jié)果,提出推薦意見(jiàn)。結(jié)果 多格列艾汀、二甲雙胍和利格列汀最終得分分別為77.0、72.3、76.2分,均強(qiáng)推薦進(jìn)入醫(yī)療機(jī)構(gòu)采購(gòu)目錄或保留使用。3種藥物均是口服降糖藥物,在治療2型糖尿病方面各有優(yōu)勢(shì),二甲雙胍是經(jīng)典藥物,在許多指南中受到一級(jí)推薦;多格列艾汀作為新藥,在降糖效果及安全性方面有優(yōu)勢(shì),在降糖的同時(shí)可改善患者β細(xì)胞功能;利格列汀作為保護(hù)胰島β細(xì)胞功能的推薦藥物,無(wú)需依據(jù)患者肝腎功能調(diào)整用藥劑量。結(jié)論 多格列艾汀、二甲雙胍和利格列汀在不同屬性中各有優(yōu)勢(shì),本次藥品遴選可為醫(yī)療機(jī)構(gòu)提供循證依據(jù)。

Objective To conduct a comprehensive clinical evaluation of dorzagliatin, metformin and linagliptin to provide a basis for the selection of drugs in medical institutions. Methods Based on the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition), the drugs were scored in terms of pharmacological properties, effectiveness, safety, economy and other attributes, and recommendations were made based on the scoring results. Results The final scores of dorzagliatin, metformin and linagliptin were 77.0, 72.3 and 76.2 respectively, and all of them were strongly recommended to be entered into the purchasing catalog of medical institutions or retained for use. The three drugs are oral hypoglycemic agents and each has its own advantages in the treatment of type 2 diabetes mellitus. Metformin is a classical drug and is recommended by the first class in many guidelines. As a new drug, dorzagliatin has advantages in glucose-lowering effect and safety, and it can improve patients' β -cell function while lowering glucose. Linagliptin is recommended as a drug to protect pancreatic β-cell function, and there is no need to adjust the dosage of the drug according to the patients' liver and kidney function. Conclusion Dorzagliatin, metformin and linagliptin have their own advantages in different attributes, and this drug selection can provide an evidence-based basis for medical institutions.

R977

國(guó)家自然科學(xué)基金資助項(xiàng)目(82003878);河北省衛(wèi)健委醫(yī)學(xué)研究指令性課題(20240157);河北省藥學(xué)會(huì)醫(yī)院藥學(xué)科研項(xiàng)目(2020-Hbsyxhms0017)